Evolutionary Genomics Stock Key Fundamental Indicators
| FNAM Stock | USD 0.0002 0.00 0.00% |
Evolutionary Genomics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.
Evolutionary Genomics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Evolutionary Genomics' valuation are provided below:Evolutionary Genomics does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Evolutionary |
Evolutionary Genomics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Evolutionary Genomics' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Evolutionary Genomics.
| 11/17/2025 |
| 02/15/2026 |
If you would invest 0.00 in Evolutionary Genomics on November 17, 2025 and sell it all today you would earn a total of 0.00 from holding Evolutionary Genomics or generate 0.0% return on investment in Evolutionary Genomics over 90 days. Evolutionary Genomics is related to or competes with Doseology Sciences, Sigyn Therapeutics, LFTD Partners, and Healthlynked Corp. Evolutionary Genomics, Inc., together with its subsidiaries, engages in the research and identification of positively se... More
Evolutionary Genomics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Evolutionary Genomics' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Evolutionary Genomics upside and downside potential and time the market with a certain degree of confidence.
Evolutionary Genomics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Evolutionary Genomics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Evolutionary Genomics' standard deviation. In reality, there are many statistical measures that can use Evolutionary Genomics historical prices to predict the future Evolutionary Genomics' volatility.Evolutionary Genomics Backtested Returns
We have found three technical indicators for Evolutionary Genomics, which you can use to evaluate the volatility of the firm. The firm shows a Beta (market volatility) of 0.0, which means not very significant fluctuations relative to the market. the returns on MARKET and Evolutionary Genomics are completely uncorrelated.
Auto-correlation | 1.00 |
Perfect predictability
Evolutionary Genomics has perfect predictability. Overlapping area represents the amount of predictability between Evolutionary Genomics time series from 17th of November 2025 to 1st of January 2026 and 1st of January 2026 to 15th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Evolutionary Genomics price movement. The serial correlation of 1.0 indicates that 100.0% of current Evolutionary Genomics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 1.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Evolutionary Genomics has a Current Valuation of 9.18 M. This is 99.94% lower than that of the Healthcare sector and 99.8% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 99.94% higher than that of the company.
Evolutionary Genomics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Evolutionary Genomics's current stock value. Our valuation model uses many indicators to compare Evolutionary Genomics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Evolutionary Genomics competition to find correlations between indicators driving Evolutionary Genomics's intrinsic value. More Info.Evolutionary Genomics is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Evolutionary Genomics' earnings, one of the primary drivers of an investment's value.Evolutionary Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Evolutionary Genomics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Evolutionary Genomics could also be used in its relative valuation, which is a method of valuing Evolutionary Genomics by comparing valuation metrics of similar companies.Evolutionary Genomics is currently under evaluation in current valuation category among its peers.
Evolutionary Fundamentals
| Return On Equity | -145.27 | |||
| Return On Asset | -0.45 | |||
| Current Valuation | 9.18 M | |||
| Shares Outstanding | 6.66 M | |||
| Shares Owned By Insiders | 32.60 % | |||
| Price To Earning | (3.79) X | |||
| Price To Sales | 352.91 X | |||
| Gross Profit | (1.23 M) | |||
| EBITDA | (1.84 M) | |||
| Net Income | (2.79 M) | |||
| Cash And Equivalents | 897.78 K | |||
| Cash Per Share | 0.14 X | |||
| Total Debt | 3.74 M | |||
| Debt To Equity | 1.81 % | |||
| Current Ratio | 9.85 X | |||
| Book Value Per Share | (1.05) X | |||
| Cash Flow From Operations | (1.58 M) | |||
| Earnings Per Share | (0.53) X | |||
| Beta | -0.0153 | |||
| Market Capitalization | 4.66 M | |||
| Total Asset | 2.93 M | |||
| Retained Earnings | (1.33 M) | |||
| Working Capital | (12.68 K) | |||
| Current Asset | 991 | |||
| Current Liabilities | 13.67 K | |||
| Z Score | 0.6 | |||
| Net Asset | 2.93 M |
About Evolutionary Genomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Evolutionary Genomics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Evolutionary Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Evolutionary Genomics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Evolutionary Genomics, Inc., together with its subsidiaries, engages in the research and identification of positively selected genes in humans, animals, and commercial crops. Evolutionary Genomics, Inc. was incorporated in 1990 and is based in Castle Rock, Colorado. Evolutionary Genomics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 2 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetOther Information on Investing in Evolutionary Pink Sheet
Evolutionary Genomics financial ratios help investors to determine whether Evolutionary Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Evolutionary with respect to the benefits of owning Evolutionary Genomics security.